Sy
No verificado

Syntis Bio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaFitnessMedicina - VariosSalud
16/07/2026
Salud
Fitness
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Ferias y Congresos
Industria
Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment
1.00
09/06/2026
Mercado laboral
Sanidad
Farmacéutica
Salud
Medicina - Varios
Syntis Bio Strengthens Leadership Team with Appointment of Matt Dallas as Chief Financial Officer
1.00
03/03/2026
Mercado laboral
Industria
Ciencia
Higiene alimentaria
Salud
Fitness
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
1.00
01/07/2025
Sanidad
Salud
Fitness
Medicina - Varios
Biotecnología
Farmacéutica
Mercado laboral
Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0